A multicentre, randomized, double-blind, parallel group, placebo-controlled, Phase 3 efficacy and safety study of Benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-acting β2-agonist in patients wtih uncontrolled asthma (SIROCCO)